A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Inc.
Eisai Inc.
University of Michigan Rogel Cancer Center
Fred Hutchinson Cancer Center
Udayana University
Ezisurg Medical Co. Ltd.
Bayer
University of Florida
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Sanofi
Sanofi
National Taiwan University Hospital
Centre Francois Baclesse
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Sichuan Enray Pharmaceutical Sciences Company
Medical College of Wisconsin
Fudan University
University Medical Center Groningen
Dana-Farber Cancer Institute
TransThera Sciences (Nanjing), Inc.
Stanford University
Hoffmann-La Roche
Mayo Clinic
Seoul National University Hospital
Alume Biosciences, Inc.
Thomas Jefferson University
The First Affiliated Hospital of Zhengzhou University
Osaka University
University of Foggia
The First Affiliated Hospital of Xiamen University
Vastra Gotaland Region
National Cancer Institute (NCI)
Aristotle University Of Thessaloniki
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Centro de Excelencia en Enfermedades de Cabeza y Cuello
Rutgers, The State University of New Jersey
Chongqing General Hospital
Institut National de la Santé Et de la Recherche Médicale, France
The First Affiliated Hospital of Zhengzhou University
Regina Elena Cancer Institute
Chongqing General Hospital
Rigshospitalet, Denmark
Vanderbilt-Ingram Cancer Center
Yeditepe University
Royal Marsden NHS Foundation Trust
Chinese PLA General Hospital
Inha University Hospital
University Medical Center Groningen